Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
Insulet's Q2 Omnipod revenues grew 23.8% at constant currency with expanding global adoption, particularly for its Omnipod 5 automated insulin delivery system. The company raised 2026 international guidance and is progressing on next-generation products including Omnipod 6. However, intense competition, macroeconomic pressures, and supply chain risks could limit future margin expansion and profitability.